Condition: Relapsed/Refractory B-cell Malignancies · Sponsor: Accutar Biotechnology Inc
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
This description comes directly from the study's public registry record.
Accutar Biotechnology · 908-340-0879 · medical@accutarbio.com
Always discuss trial participation with your own doctor first.
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| University of North Carolina | Chapel Hill, North Carolina, United States | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| The Ohio State University - The James Cancer Hospital and Solove Research Institute | Columbus, Ohio, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Withdrawn |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Swedish Cancer Institute | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05780034